ALT - Company ID 0001326190
The table below shows Altimmune, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$20.94M | -$16.84M | -$16.36M | -$19.41M | -$13.53M | -$19.57M |
| Capital expenditure | $21.00K | - | - | $51.00K | $9.00K | $4.21M |
| Investing cash flow | -$3.69M | -$5.10M | -$39.52M | $13.30M | -$9.00K | $19.16M |
| Dividends paid | - | - | - |
Altimmune, Inc. reported operating cash flow of -$67.53M for fiscal year 2025. That is up 15.4% from -$79.85M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.32M (FY 2012) to -$67.53M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $78.47M | $34.12M | -$261.00K | -$302.00K | $3.18M | $34.42M |